GlassScriptPhysician profile
Lakshmi Aggarwal
NPI 1528060431
$1,371.27
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $3.22 · 2021: $65.78 · 2022: $86.62 · 2023: $373 · 2024: $14.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $146.27 | 2019-2022 | |
| Genentech USA, INC. | $129.60 | 2019 | |
| Amgen INC. | $124.20 | 2023 | Lumakras |
| Karyopharm Therapeutics INC. | $123.50 | 2023 | Xpovio |
| Astellas Pharma US INC | $123.43 | 2019 | |
| Verastem, INC. | $119.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $113.29 | 2019 | |
| Rigel Pharmaceuticals, INC. | $76.72 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $58.10 | 2022-2023 | Epkinly |
| Astrazeneca Pharmaceuticals LP | $54.32 | 2019 | |
| Kite Pharma, INC. | $53.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $35.74 | 2019-2023 | |
| Pfizer INC. | $30.54 | 2019 | |
| Celgene Corporation | $24.17 | 2023 | Pomalyst |
| G1 Therapeutics, INC. | $20.83 | 2023 | Cosela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 108 LLC | $20.61 | 2019 | |
| Aadi Bioscience, INC. | $19.18 | 2023 | Fyarro |
| Exelixis INC. | $18.17 | 2023 | Cabometyx |
| Merck Sharp & Dohme LLC | $16.27 | 2019 | |
| Abbvie INC. | $14.49 | 2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Glaxosmithkline, LLC. | $11.74 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.41 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.84 | 2019 | |
| Clovis Oncology, INC. | $3.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lakshmi Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.